IGPH — IGEA Pharma NV Income Statement
0.000.00%
Last trade - 00:00
- CH₣0.51m
- CH₣0.90m
2018 December 31st | 2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | Final | Final |
Revenue | |||||
Total Revenue | 0.005 | 0.001 | 0.069 | 0.103 | 0 |
Cost of Revenue | |||||
Gross Profit | -0.163 | -0.243 | -0.186 | -0.023 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.25 | 1.73 | 0.916 | 1.25 | 11.8 |
Operating Profit | -1.24 | -1.72 | -0.847 | -1.15 | -11.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.21 | -1.7 | -0.999 | -1.26 | -11.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.21 | -1.7 | -1 | -1.26 | -11.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.21 | -1.7 | -0.992 | -1.23 | -11.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.21 | -1.7 | -0.992 | -1.23 | -11.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.053 | -0.062 | -0.04 | -0.004 | -0.03 |